The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics Inc. participated in a Research Breakfast hosted by ACS CAN, underlining its alignment with advocates of evidence-based cancer policy.
The company reiterated its dedication to supporting initiatives that reduce the cancer burden and to developing meaningful therapies for patients. Bicara Therapeutics Inc. expressed gratitude for the opportunity to contribute alongside the advocacy group, indicating a continued partnership in the pursuit of improved patient outcomes.
Bicara recently announced Ficerafusp alfa as the first EGFR-directed antibody-TGF-beta trap for HPV-negative HNSCC. The company has also initiated the FORTIFI clinical trial to address unmet needs for HPV-negative HNSCC patients with poor prognosis. These efforts reflect Bicara’s focus on advancing new treatment options for cancer patients.